Market Signal Briefing

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

A bold claim is spreading in crypto circles that XRP might not just be a payments and settlement token anymore. According to a popular crypto analyst, the next upward move for the altcoin could position it as an Ethereum killer. At the same time, other voices are urging holders to watch for new signs that the next rally could be nearer than most expect.

XRP’s Pure Chart And The Ethereum Killer Narrative
XRP is slowly returning to bullish sentiment with a steady recovery from the weekend’s market-wide crypto crash. Interestingly, a new narrative is building up among investors, with a well-known analyst known as Alex Cobb on social media platform X predicting the cryptocurrency to kill Ethereum in its next rally. 

The dramatic label came when legendary trader Peter Brandt shared a long-term chart showing XRP’s price action in a symmetrical consolidation pattern on the weekly candlestick timeframe. “Has there ever been a purer long-term chart?” Brandt questioned.

The chart structure shows the price breaking above a long-term symmetrical triangle in late 2024, but it has been consolidating between a relatively stable range since then. The expectation is that once this upper range is broken, it will lead to a strong follow-through for the token’s price. 

Source: Chart from Peter Brandt on X
The chart’s clarity and structure drew the attention of many crypto participants, and analyst Alex Cobb interpreted it as a signal of a coming breakout destined to challenge Ethereum. “The next leg up on XRP will be the Ethereum killer,” he said. 

Cobb’s claim is based on a simple but powerful idea that resonates with many XRP enthusiasts. Whenever the altcoin finally breaks out cleanly and sustains upward momentum, then the amount of inflow will be enough for it to challenge Ethereum as the largest altcoin. Notably, this outcome is also dependent on the success of Spot XRP ETFs, if and when they finally hit the US market.

Liquidity, On-Chain Signals, And The Next Wave
Outside of XRP’s price charts, some analysts are looking at capital flows and on-chain signals as the real engines for the next leg. For instance, crypto analyst Ripple Bull Winkle believes that the next major wave for the token is much closer than most people think. 

His perspective is based on a growing shift in blockchain liquidity that he says signals a new phase of market movement. Earlier this week, more than $250 million in USDC was minted at the USDC Treasury, and according to Bull Winkle, such a large stablecoin issuance is not coincidental. 

It represents institutional liquidity preparing to move into some cryptocurrencies, the token included as a natural conduit. “Brace yourselves, everyone. XRP is about to make history,” he said.

At the time of writing, the token is trading at $2.51, up by 1.5% in the past 24 hours.

XRP trading at $2.49 on the 1D chart | Source: XRPUSDT on Tradingview.com
Featured image from iStock, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts.
Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

Ethereum (ETH) is back in the spotlight after Fidelity clients purchased roughly 36,460 ETH ($154.6 million), signaling renewed institutional demand even as spot ETH ETFs logged heavy redemptions.

Before stabilizing around $4,100, the second-largest cryptocurrency briefly dipped below $4,000 this week, but several analysts argue the pullback places ETH in a key “buy zone” ahead of a potential push toward new highs.

ETH's price trends to the upside on the daily chart. Source: ETHUSD on Tradingview
Fidelity Steps In as ETFs See Redemptions

Fidelity’s reported buy spotlights a growing trend as traditional finance is steadily increasing exposure to Ethereum’s smart-contract ecosystem, staking yields, and tokenization upside.

The move contrasts with the latest ETF flow picture, where spot ETH products saw about $428 million in outflows in a single day, led by $310 million from BlackRock’s fund. While redemptions weighed on price near term, primary-market creations like Fidelity’s purchase can tighten available supply and stabilize spot liquidity.

Outflows and Liquidations Test Nerves
Macro jitters and tariff headlines helped trigger a sharp selloff, sending ETH down 6.5% on Oct. 14 and sparking $145 million in liquidations in 24 hours, per derivatives trackers.

That forced unwinding pushed price through the $4,000 handle, but technicians note ETH is retesting prior resistance-turned-support and still carving a bullish flag structure on higher time frames.

Popular trader Michael van de Poppe argues ETH likely just needs a higher low to reassert momentum, eyeing a recovery toward $5,000 first and then $6,250 if buyers reclaim control.

Ethereum Price Outlook: Key Levels to Watch
Near term, bulls want to see an Ethereum price balance back above $4,000–$4,211, followed by a decisive break of the $5,000 psychological level to unlock the $6,250 target many chartists flag via tools like Murrey Math and measured-move projections.

On the downside, traders are watching $3,626 as interim support; a daily close below $3,425 would dent the bullish structure and argue for deeper consolidation.

Despite headline outflows, the Fidelity inflow highlights sticky institutional interest in Ethereum’s role across DeFi, NFTs, and real-world asset tokenization, plus the structural tailwind from staking yields.

If ETF redemptions cool and spot demand returns, ETH’s recent dip could prove a buy-the-pullback setup on the path toward new cycle highs.

Cover image from ChatGPT, ETHUSD on Tradingview

Bitcoin surged to a record high last week before experiencing a dramatic setback, raising questions about whether the so-called debasement trade still holds for crypto traders seeking protection against currency erosion.

In brief
Bitcoin is in a critical confidence-rebuilding phase after last week’s liquidation cascade, Decrypt was told.
Experts are divided, with some seeing a market bottom and others warning of persistent headwinds.
Sustainable recovery depends on improved macro conditions and the return of institutional demand.
Bitcoin’s latest pullback has cleared the decks for a potential rebound, but conviction is scarce.

“It was a structural flaw magnified by excessive leverage and thin liquidity,” Thiago Duarte, Market Analyst at Axi, told Decrypt.

After a $19 billion leverage washout and cooling ETF demand last Friday, the market is now in a wait-and-see mode. Analysts say the sell-off was more structural than fundamental, flushing excess speculation rather than signaling a broader exodus.

It has also pushed Bitcoin into a critical zone, between $108,400 and $117,100, a range where over 5% of the supply is held at a loss.

Without a renewed catalyst to lift prices back above $117,100, the market risks deeper contraction, especially if there’s a sustained break below the lower limit of the said range. That would signal "structural weakness" and risk a deeper correction, Glassnode wrote in a report on Wednesday.

“The crypto market is still in a confidence-rebuilding and bottom-forming phase,” Tim Sun, senior researcher at HashKey Group, told Decrypt. 

“The duration of this stage largely depends on macro conditions,” Sun added, pointing to ongoing trade tensions and tight global liquidity.

Multiplying the headwinds are long-term investors trimming their holdings by roughly 300,000 BTC total, hinting at steady profit-taking.

​​Sun echoed uncertainty in the near-term future, noting that market sentiment remains “highly sensitive to news flow and macro indicators,”  and that the recent deleveraging event “could temporarily slow institutional inflows.”

Despite the near-term caution, K33 Research’s Tuesday note argued that similar open interest flushes “have tended to align with market bottoms,” suggesting the worst of the selling may be over.

The foundation for a recovery, according to K33, remains intact due to a “supportive backdrop, including expansionary policy expectations, high institutional demand, and pending ETF catalysts.”

“If risk sentiment stabilizes, Bitcoin could retest the upper range fairly quickly,” Robin Singh, CEO of a cryptocurrency portfolio tracking and tax software Koinly, told Decrypt. “However, continued uncertainty around trade policy or U.S. inflation data could keep prices choppy through the next week or two.”

Glassnode, however, takes a more cautious approach, noting that Bitcoin’s recovery is contingent on the return of steady ETF buying and renewed on-chain accumulation.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Paxos mistakenly minted $300 trillion of PayPal's PYUSD stablecoin before quickly burning the excess, marking one of the largest on-chain errors recorded.

Journalist

Posted: October 16, 2025

Key Takeaways
Why is Dogecoin under pressure after the whale transfer?
A 132 million DOGE inflow to Robinhood has raised concerns of large-scale selling, amplifying short-term market uncertainty.

What signals DOGE’s overvaluation?
Dogecoin’s NVT Ratio surged to 287, hinting at stretched network value.

Dogecoin [DOGE] witnessed a massive transfer of 132 million tokens, worth $27 million, from an unknown wallet to Robinhood, sparking fears of heightened selling activity. 

Historically, such whale transfers have often preceded short-term price pullbacks, as large holders typically move funds to exchanges before selling.

The transaction’s timing, combined with fading retail demand, highlights the growing market influence of whales. With liquidity thinning across exchanges, any large sell order could heighten volatility.

Still, the absence of a sharp price drop right after the transfer showed traders were cautious but not panicking.

Can bulls defend $0.22 support?
Dogecoin continued to trade within an ascending channel, but faced repeated rejections near the $0.22 resistance.

The price hovered close to the $0.18–$0.20 demand zone, a key region where bulls attempted to prevent further decline.

The RSI at 39.99 reflected weak buying momentum and mild bearish sentiment.

However, as long as DOGE holds above $0.18, the broader channel structure allows room for a rebound.

A sustained close above $0.22 might invalidate the current bearish bias and set up a short-term relief rally.

Source: TradingView

Taker-sell dominance confirms bearish control
According to Spot Taker CVD data from CryptoQuant, sell-side dominance has persisted across the last 90 days, confirming that sellers maintained control in the Derivatives market.

The imbalance between taker buys and sells signaled lower trader confidence, with many leveraged longs closing their positions.

This steady pressure has reduced liquidity depth and raised the probability of sharp intraday swings.

Still, a sudden short squeeze could give bulls temporary relief, though current sell activity continues to outweigh buying efforts.

NVT surge raises concerns about Dogecoin’s valuation
Santiment data showed Dogecoin’s NVT Ratio surged to 287, suggesting that market value outpaced on-chain activity. This typically signals an overvalued network and reduced transaction efficiency.

Historically, similar spikes have preceded corrections as speculative sentiment overtook real utility.

A rise in transaction volume would help stabilize valuation metrics and restore confidence, but until then, the high NVT ratio remains a red flag for investors.

Will DOGE avoid another breakdown?
Dogecoin’s outlook remained fragile as whales moved large sums onto exchanges and sell-side dominance intensified. The memecoin’s ability to hold above $0.18 could define its short-term trajectory. 

A successful defense may spark renewed buying interest and push DOGE back toward $0.22, while a breakdown could trigger extended losses toward lower supports. 

For now, sentiment leans bearish, and sustained inflows to trading platforms suggest further caution is warranted among traders awaiting a potential rebound.

XRP price started a consolidation phase below $2.60. The price is now showing positive signs but faces a major resistance near $2.50 and $2.60.

XRP price is attempting a recovery wave above the $2.420 zone.
The price is now trading below $2.50 and the 100-hourly Simple Moving Average.
There is a key bearish trend line forming with resistance at $2.50 on the hourly chart of the XRP/USD pair (data source from Kraken).
The pair could start a fresh surge if it clears the $2.60 resistance.

XRP Price Faces Key Resistance
XRP price found support and started a strong recovery wave above $2.30, like Bitcoin and Ethereum. The price was able to climb above the $2.350 and $2.40 levels to enter a positive zone.

The bulls were able to push the price above the 61.8% Fib retracement level of the downward wave from the $3.05 swing high to the $1.40 swing low. However, the bears are still active near the $2.550 and $2.60 levels. Besides, there is a key bearish trend line forming with resistance at $2.50 on the hourly chart of the XRP/USD pair.

The price is now trading below $2.50 and the 100-hourly Simple Moving Average. If there is a fresh upward move, the price might face resistance near the $2.50 level and the trend line.

Source: XRPUSD on TradingView.com
The first major resistance is near the $2.60 level, above which the price could rise and test the 76.4% Fib retracement level of the downward wave from the $3.05 swing high to the $1.40 swing low at $2.660. A clear move above the $2.660 resistance might send the price toward the $2.750 resistance. Any more gains might send the price toward the $2.780 resistance. The next major hurdle for the bulls might be near $2.820.

Another Drop?
If XRP fails to clear the $2.50 resistance zone, it could start a fresh decline. Initial support on the downside is near the $2.40 level. The next major support is near the $2.30 level.

If there is a downside break and a close below the $2.30 level, the price might continue to decline toward $2.2420. The next major support sits near the $2.220 zone, below which the price could continue lower toward $2.120.

Technical Indicators

Hourly MACD – The MACD for XRP/USD is now losing pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for XRP/USD is now below the 50 level.

Major Support Levels – $2.40 and $2.30.

Major Resistance Levels – $2.50 and $2.60.

At the D.C. Fintech Week, Ripple CEO Brad Garlinghouse once again addressed one of the biggest misconceptions in the crypto industry, that Ripple controls XRP. He said that while Ripple is a company with its own leadership, XRP operates as an open-source technology supported by a wide community of independent developers, companies, and users.

Garlinghouse pointed out that many people mistakenly treat XRP as a company with a single leadership figure. Instead, it functions through a decentralized ecosystem where hundreds of independent builders contribute to the XRP Ledger.

“People say things like, ‘Well, XRP has a CEO.’ I’m like who is it? Ripple has a CEO. That’s me. But there are scores, if not hundreds, of other CEOs building around the XRP ecosystem.,” he said.

Ripple’s Legal Fight and Industry RoleGarlinghouse also shed light on Ripple’s lengthy legal battle with the U.S. Securities and Exchange Commission. The company spent nearly $150 million defending itself to achieve legal clarity that XRP is not a security. He said that Ripple fought the case not only for its own sake but also for broader regulatory understanding within the crypto industry.

Ripple continues to support the development of a transparent, multi-chain ecosystem and remains a major investor in blockchain innovation. Garlinghouse reaffirmed that Ripple’s goal is to drive real-world utility through crypto, not control it.

Open-Source Governance and IndependenceThe XRP Ledger operates under a governance system that reflects its open-source nature. Network changes and amendments require approval from a large majority of validators, not Ripple alone. There have been cases where Ripple opposed certain proposals that were still approved by the community, showing that the company does not control XRP’s direction.

This governance model has been one of XRP’s key strengths, allowing it to evolve independently of Ripple’s internal decisions while maintaining security and decentralization.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Vontier Corporation (NYSE:VNT) Shareholder/Analyst Call October 15, 2025 9:00 AM EDT

Company Participants

Ryan Edelman - Vice President of Investor Relations
Mark Morelli - President, CEO & Director
Mark Williams
Andrew Bennett
Devon Watson
Austin Lieb
Andrew Bennet
Anshooman Aga - Senior VP & CFO
Elaine Kanak

Conference Call Participants

Julian Mitchell - Barclays Bank PLC, Research Division
Tracy Long
Dan Munford
Elaine Mohr
Nigel Coe - Wolfe Research, LLC
Robert Mason - Robert W. Baird & Co. Incorporated, Research Division
Katie Fleischer - KeyBanc Capital Markets Inc., Research Division

Conversation

Ryan Edelman
Vice President of Investor Relations

All right. Good morning, everybody. We're going to go ahead and get started here. So, first off, I want to say thank you to everyone who could be here with us in Chicago today, and thank you to those of you listening on the webcast. We know it's a busy time for all of you, so we appreciate your interest in Vontier, and we appreciate you taking the time today.

So just to give you a little lay of the land, we're here at NACS, which is the National Association of Convenience Stores, largest annual trade show of the year. It's sort of a massive show, a lot of excitement going on, a lot of folks here. But we wanted to bring you here just in an effort to help address a lot of your questions. We get a lot of questions, Mark, Anshooman and I when we're with you around the businesses, how they come together and just broadly more detail about the convenience retail end market. So we're hopefully going to spend a lot of time on that today. And our intent is to really help educate you here on this end market. We want to give you a better understanding of our strategic vision. We want to share with you our conviction for the growth drivers in this end market and how we're creating significant opportunities and

Recommended For You

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASDAQ: SMLR) between March 10, 2021 and April 15, 2025, both dates inclusive (the “Class Period”), of the important October 28, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Semler Scientific securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Semler Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=39889 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Semler Scientific did not disclose a material investigation by the United States Department of Justice (the "DOJ") into violations of the False Claims Act, while discussing possible violations of the False Claims Act (and aggressive DOJ enforcement thereof) in hypothetical terms; and (2) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Semler Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=39889 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 28, 2025 to file lead plaintiff applications in a securities class action lawsuit against Dow Inc. (NYSE: DOW), if they purchased the Company’s securities between January 30, 2025 and July 23, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Michigan.

Get Help

Dow investors should visit us at https://claimsfiler.com/cases/nyse-dow-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Dow and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On July 24, 2025, the Company disclosed a 2Q 2025 non-GAAP loss per share of $0.42, much larger than the approximate $0.17 to $0.18 per share loss expected by analysts, and net sales of $10.1 billion, representing a 7.3% year-over-year decline and missing consensus estimates by $130 million, “reflecting declines in all operating segments” due in part to “the lower-for-longer earnings environment that our industry is facing, amplified by recent trade and tariff uncertainties.” Further, the Company disclosed that it was cutting its dividend in half, from $0.70 per share to only $0.35 per share, citing the need for “financial flexibility amidst a persistently challenging macroeconomic environment.”

On this news, the price of Dow’s shares fell $5.30 per share, or 17.45%, to close at $25.07 per share on July 24, 2025.  

The case is Sarti v. Dow Inc., No. 25-cv-12744.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of National Grid plc (NYSE: NGG) resulting from allegations that National Grid plc may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased National Grid securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=41344 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On July 2, 2025, Reuters published an article entitled “‘Preventable’ National Grid failures led to Heathrow fire, findings say.” The article stated that a “fire that shut London’s Heathrow airport in March, stranding thousands of people, was caused by the UK power grid’s failure to maintain an electricity substation, an official report said on Wednesday, prompting the energy watchdog to open a probe.” Further, the article stated that the United Kingdom’s Energy minister, Ed Miliband, had “called the report “deeply concerning”, after it concluded that the issue which caused the fire was identified seven years ago but went unaddressed by power grid operator National Grid[.]”

On this news, National Grid’s American Depositary Shares (“ADSs”) fell 5%, on July 2, 2024.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 18, 2025 to file lead plaintiff applications in a securities class action lawsuit against KBR, Inc. (NYSE: KBR), if they purchased or otherwise acquired the Company’s securities between May 6, 2025 and June 19, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Texas.

Get Help

KBR investors should visit us at https://www.claimsfiler.com/cases/nyse-kbr-1 or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

KBR and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On June 19, 2025, HomeSafe Alliance (“HomeSafe”), a KBR joint venture in which KBR has a 72% economic interest, disclosed that it received “a notice from the U.S. Department of Defense's Transportation Command (TRANSCOM) terminating the Global Household Goods Contract, which HomeSafe won in 2021 to transform the military move system for the benefit of service members and their families.”

On this news, the price of KBR’s shares fell $3.85 per share, or 7.29%, to close at $48.93 on June 20, 2025. On June 23, 2025, the next trading day, KBR stock fell a further $1.30, or 2.65%, to close at $47.63 on June 23, 2025.

The case is Norrman v. KBR, Inc., et al., No. 25-cv-04464.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 2, 2025 to file lead plaintiff applications in a securities class action lawsuit against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH), if they purchased or otherwise acquired the Company’s securities between February 5, 2025 and July 23, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

Get Help

Molina Healthcare investors should visit us at https://claimsfiler.com/cases/nyse-moh-2/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Molina Healthcare and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On July 23, 2025, the Company reported its financial results for the second quarter ended June 30, 2025 and cut its full-year 2025 earnings guidance, disclosing that “GAAP net income was $4.75 per diluted share for the second quarter of 2025, a decrease of 8% year over year” and it “now expects its full year 2025 adjusted earnings to be no less than $19.00 per diluted share,” due to a “challenging medical cost trend environment,” including “utilization of behavioral health, pharmacy, and inpatient and outpatient services.”

On this news, the price of Molina’s shares fell $32.03, or 16.84%, to close at $158.22 per share on July 24, 2025, on unusually heavy trading volume.

The case is Hindlemann v. Molina Healthcare, Inc., et al., No. 2:25-cv-09461.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 8, 2025 to file lead plaintiff applications in a securities class action lawsuit against Marex Group plc (“Marex” or the “Company”) (NasdaqGS: MRX), if they purchased or otherwise acquired the Company’s securities between May 16, 2024 and August 5, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Get Help

Marex investors should visit us at https://claimsfiler.com/cases/nasdaq-mrx/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Marex and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 5, 2025, NINGI Research reported numerous allegations about the Company including, among other things, that it “has engaged in a multi-year accounting scheme involving a web of opaque off-balance-sheet entities, fictitious intercompany transactions, and misleading disclosures to conceal significant losses, inflate profits, and mask its true risk exposure” and that it has “numerous multi-million-dollar discrepancies in intercompany receivables and loans across Marex’s sprawling network of 56+ entities.” The report further identified “a $17 million receivable created out of thin air, a subsidiary whose reported profit was inflated by 150% in group filings before being liquidated, and an asset valued at $14.9 million that was sold to Robinhood for just $2.5 million weeks later, with no reported loss” and that the Company concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund it both controls and trades with, and that it is using the fund to generate non-cash trading profits and inflate operating cash flow by misclassifying structured note issuance as income.

On this news, the price of Marex’s shares fell $2.33, or 6.2%, to close at $35.31 per share on August 5, 2025, on unusually heavy trading volume.

The case is Narayanan v. Marex Group PLC, et al., No. 25-cv-08393.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Snap Inc. (NYSE: SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), both dates inclusive, of the important October 20, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Snap securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Snap class action, go to https://rosenlegal.com/submit-form/?case_id=2663 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Snap’s expected advertising revenue and anticipated growth while emphasizing potential macroeconomic instability. In truth, Snap’s optimistic reports of advertising growth and earnings potential fell short of reality as they relied far too heavily on Snap’s ability to execute on its potential; Snap was already experiencing the ramifications of a significant execution error when defendants’ claimed a lack of visibility due to macroeconomic conditions. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Snap class action, go to https://rosenlegal.com/submit-form/?case_id=2663 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SNOW over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

LOS ANGELES--(BUSINESS WIRE)--Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR.

Chief Financial Officers now play a critical role in shaping corporate strategy and positioning organizations to meet future challenges. This episode profiles CFO Natasha Fernandes of IMAX.

October 15, 2025 9:42 PM EDT | Source: American Critical Minerals Corp.
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2025) - American Critical Minerals Corp. (CSE: KCLI) (OTCQB: APCOF) (FSE: 2P30) ("American Critical Minerals" or the "Company") is pleased to announce that it has entered into an agreement with Research Capital Corporation as the sole underwriter and sole bookrunner, (the "Underwriter"), pursuant to which the Underwriter has agreed to purchase, on a bought deal basis, 11,429,000 units of the Company (the "Units") at a price of $0.35 per Unit (the "Offering Price") for aggregate gross proceeds to the Company of $4,000,150 (the "Offering").

In addition, the Company is also pleased to announce a concurrent non-brokered private placement of up to 5,714,286 Units at a price of $0.35 per Unit for gross proceeds of up to $2,000,000 (the "Non-Brokered Private Placement"). Together with the Offering and the Non-Brokered Private Placement, the Company expects to raise aggregate gross proceeds of up to $6,000,000.

Each Unit shall be comprised of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant of the Company (each whole warrant, a "Warrant"). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $0.45 per Common Share for a period of 36 months following closing of the Offering, provided that holders will not be permitted to exercise Warrants until 60 days following closing of the Offering.

The net proceeds from the Offering of the Units will be used for working capital and general corporate purposes.

The Company has granted to the Underwriter an option (the "Underwriters' Option") to increase the size of the Offering by up to an additional number of Units, that in aggregate would be equal to 15% of the total number of Units to be issued under the Offering, exercisable at any time up to 48 hours prior to the closing of the Offering.

The Units to be issued under the Offering and the Non-Brokered Private Placement will be offered for sale pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended by CSA Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (collectively, the "Listed Issuer Financing Exemption"), in all provinces of Canada, except Quebec, and other qualifying jurisdictions, including the United States. The Units offered under the Listed Issuer Financing Exemption will be immediately "free-trading" under applicable Canadian securities laws.

There is an offering document (the "Offering Document") related to this Offering and Non-Brokered Private Placement that can be accessed under the Company's profile at www.sedarplus.ca and at the Company's website at www.acmineralscorp.com. Prospective investors should read this Offering Document before making an investment decision.

The closing of the Offering and the Non-Brokered Private Placement are expected to occur on or about the week of October 27, 2025 (the "Closing"), or such other earlier or later date as the Underwriter may determine. Closing is subject to the Company receiving all necessary regulatory approvals, including the conditional approval of the Canadian Securities Exchange.

The Underwriter will receive a cash commission of 7.0% of the aggregate gross proceeds of the Offering and such number of broker warrants (the "Broker Warrants") as is equal to 7.0% of the number of Units sold under the Offering. Each Broker Warrant entitles the holder to purchase one Unit at an exercise price equal to the Offering Price for a period of 36 months following the Closing.

This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

About American Critical Minerals' Green River Potash and Lithium Project

The Green River Potash and Lithium Project is situated within Utah's highly productive Paradox Basin, located 20 miles northwest of Moab, Utah and has significant logistical advantages including close proximity to major rail hubs, airport, roads, water, towns and labour markets. It also benefits from close proximity to the agricultural and industrial heartland of America and numerous potential end-users for its products.

The history of oil and gas production across the Paradox Basin provides geologic data from historic wells across the Project, and the wider Basin, validating and de-risking the potential for high grade potash and large amounts of contained lithium. Wells in and around the project reported lithium up to 500 ppm, bromine up to 6,100 ppm and boron up to 1,260 ppm (Gilbride & Santos, 2012). This data is reinforced by nearby potash production and the advanced stage of neighbouring lithium projects. The Paradox Basin is believed to contain up to 56 billion tonnes of lithium brines, potentially the largest such resource in US (Source: Anson Fastmarkets Presentation – https://wcsecure.weblink.com.au/pdf/ASN/02823465.pdf) The Company also has a 43-101 Exploration Target of 600 million to 1 billion tonnes of sylvinite (the most important source for the production of potash in North America) with average grades ranging from 19% to 29% KCL.**

The Company holds a 100% interest in eleven State of Utah ("SITLA") mineral and minerals salt leases covering approximately 7,050 acres, 1,094 federal lithium brine claims (BLM Placer Claims) covering 21,150 acres, and 11 federal (BLM) potash prospecting permits covering approximately 25,480 acres. Through these leases, permits and claims the Company has the ability to explore for potash, lithium and potential by-products across the entire Green River Project (approx. 32,530 acres). The Company is authorized to drill a total of 7 drill holes across the Project (pending bonding the recently approved 4 drill holes).

Intrepid Potash, Inc. is America's largest potash company and only U.S. domestic potash producer and currently produces potash from its nearby Moab Solution Mine, which the Company believes provides strong evidence of stratigraphic continuity within this part of the Paradox Basin (www.intrepidpotash.com). Anson Resources Ltd. has advanced lithium development projects contiguous to the northern boundary of our Green River Project and neighbouring to the south. Anson has a large initial resource, robust definitive feasibility study and has recently completed successful piloting operations through its partnership with Koch Technology Solutions, as well as an offtake agreement with LG Energy Solution. The Anson exploration targets encompass the combined Mississippian Leadville Formation and the Pennsylvanian Paradox Formation brine-bearing clastic layers, which also underlie American Critical Minerals' entire project area (www.ansonresources.com)*.

In 2022, the U.S. imported approx. 96.5% of its annual potash requirements with domestic producers receiving a higher sales price due to proximity to market (intrepidpotash.com/ August 15, 2024, Investor Presentation). In March 2024, the US Senate introduced a bill to include key fertilizers and potash on the US Department of Interior list of Critical Minerals which already includes lithium, and this process is well advanced with potash being added to the USGS Draft Critical Minerals List. In August 2025. Recent market estimates suggest that the global potash market is over US$50 billion annually and growing at a compound annual growth rate ("CAGR") of close to 5%. Annual lithium demand is now estimated to be over 1 million tonnes globally and continuing to grow rapidly. * **

*American Critical Minerals' management cautions that results or discoveries on properties in proximity to the American Critical Minerals' properties may not necessarily be indicative of the presence of mineralization on the Company's properties.

**A report titled "NI 43-101 Technical Report - Green River Potash Project, Grand County, Utah, USA", prepared by Agapito Associates Inc., and dated effective September 12, 2012, quantifies the Green River Potash Project's potash exploration potential in the form of a NI 43-101 Exploration Target. The Exploration Target estimate was prepared in accordance with the National Instrument 43-101 –Standards of Disclosure for Mineral Projects ("NI 43-101"). It should be noted that Exploration Targets are conceptual in nature and there has been insufficient exploration to define them as Mineral Resources, and, while reasonable potential may exist, it is uncertain whether further exploration will result in the determination of a Mineral Resource under NI 43-101. The Exploration Target stated in the Agapito Report is not being reported as part of any Mineral Resource or Mineral Reserve. A copy of the report can be accessed on the corporate website for the Company: www.acmineralscorp.com.

***United States Geological Survey, Mineral Commodity Summaries, January 2024 (https://pubs.usgs.gov/periodicals/mcs2024/mcs2024-potash.pdf).

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains forward-looking information within the meaning of applicable securities legislation. Forward-looking information is typically identified by words such as: believe, uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Important factors that could cause actual results to differ from this forward-looking information include those described under the heading "Risks and Uncertainties" in the Company's most recently filed MD&A. The Company does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Readers are cautioned not to place undue reliance on forward-looking expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. Such statements include, without limitation, statements regarding the intended use of proceeds from the Offering. Although the Company believes that such statements are reasonable, it can give no assurances that such expectations will prove to be correct. All such forward-looking information is based on certain assumptions and analyses made by the Company in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. This information, however, is subject to a variety of risks and information.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270645

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important October 27, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased LifeMD securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the LifeMD class action, go to https://rosenlegal.com/submit-form/?case_id=43404 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 27, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated LifeMD’s competitive position; (2) defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the LifeMD class action, go to https://rosenlegal.com/submit-form/?case_id=43404 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

LOS ANGELES--(BUSINESS WIRE)--America's Car-Mart, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – CRMT.

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Tronox Holdings plc (NYSE: TROX) between February 12, 2025 and July 30, 2025, both dates inclusive (the “Class Period”), of the important November 3, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Tronox common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Tronox class action, go to https://rosenlegal.com/submit-form/?case_id=44403 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made statements regarding Tronox’s overall expected growth and strength in its pigment and zircon commercial division. The lawsuit alleges that defendants made overwhelmingly positive statements to investors regarding these divisions, as well as on its ability to achieve 2025 revenue growth projections, to investors while at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Tronox’s ability to forecast the demand for its pigment and zircon products or otherwise the true state of its commercial division, despite making lofty long-term projections, Tronox’s forecasting processes fell short as sales continued to decline and costs increased, ultimately, derailing Tronox’s revenue projections. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Tronox class action, go to https://rosenlegal.com/submit-form/?case_id=44403 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nutex Health Inc. (NASDAQ: NUTX) between August 8, 2024 and August 14, 2025, both dates inclusive (the “Class Period”), of the important October 21, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Nutex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Nutex class action, go to https://rosenlegal.com/submit-form/?case_id=43936 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 21, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) HaloMD, a third-party independent dispute resolution vendor (“IDR”), was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (2) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to Nutex’s engagement with HaloMD in the IDR process were unsustainable; (3) in addition, Nutex overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (4) as a result, Nutex was unable to effectively account for the treatment of certain of its stock based compensation obligations; (5) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (6) the foregoing increased the risk that Nutex would be unable to timely file certain financial reports with the SEC; (7) accordingly, Nutex’s business and/or financial prospects were overstated; and (8) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Nutex class action, go to https://rosenlegal.com/submit-form/?case_id=43936 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

, /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025. MoonLake is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), particularly in dermatology and rheumatology.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that MoonLake Immunotherapeutics (MLTX) Mislead Investors Regarding the Efficacy of its Drug Candidate  

According to the complaint, during the class period, defendants disclose material facts, regarding the distinction between the Nanobodies and monoclonal antibodies, including that: (1) that SLK (MoonLake's phase 2 drug) and BIMZELX (the FDA approved drug against which SLK would have to demonstrate superior efficacy) share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) that SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK's distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK's purported superiority to monoclonal antibodies.

Plaintiff alleges that on September 28, 2025, MoonLake announced week-16 results from its Phase 3 VELA program. The results showed that SLK failed to demonstrate competitive efficacy relative to BIMZELX. Following the announcement, MoonLake's stock price cratered, falling $55.75 per share, or 89.9%, to close at $6.24 on September 29, 2025.

Next Steps: You may be eligible to participate in the class action against MoonLake Immunotherapeutics. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by December 15, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.  You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses. 

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. 

To be notified if a class action against MoonLake Immunotherapeutics settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising.  Past results do not guarantee a similar outcome.  

SOURCE Robbins LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In